Featured Research

from universities, journals, and other organizations

Drug mitigates toxic effects of radiation in mice

Date:
June 24, 2010
Source:
University of North Carolina School of Medicine
Summary:
Medical researchers have provided one of the first examples of successful radiomitigation in mammals. The investigators found that oral treatment of mice with a drug that inhibits enzymes involved in cell division caused certain groups of bone marrow cells to temporarily stop dividing (which they termed "pharmacological quiescence" or PQ).

While radiation has therapeutic uses, too much radiation is damaging to cells. The most important acute side effect of radiation poisoning is damage to the bone marrow. The bone marrow produces all the normal blood cells, and therefore a high dose of radiation can lead to low blood counts of red cells, platelets and white blood cells. Humans that receive a lethal dose of radiation as in the setting of an accidental exposure die of bone marrow failure. While there are a few drugs that will decrease toxicity when given before exposure to radiation ("radioprotectants"); currently, no effective therapy exists to mitigate bone marrow toxicity of radiation when given after radiation exposure ("radiomitigants"). The identification of successful human radiomitigants is a top research priority of the U.S. Department of Homeland Security and National Institutes of Health.

In a study published June 23 in the Journal of Clinical Investigation, a team led by UNC Lineberger Associate Director for Translational Research, Norman Sharpless, MD, provides a first example of successful radiomitigation in mammals. The investigators found that oral treatment of mice with a drug that inhibits enzymes involved in cell division caused certain groups of bone marrow cells to temporarily stop dividing (which they termed 'pharmacological quiescence' or PQ). Several decades of work have shown that cells which are not dividing are resistant to agents that damage DNA, like radiation. Workers in the Sharpless lab were then able to show that the induction of PQ immediately before or up to 20 hours after radiation exposure were able to protect mice from a lethal dose of radiation. PQ protected all the normal cells of blood, including platelets, red cells and white cells.

"We believe this study is really exciting. We have identified a simple, non-toxic pill that decreases radiation toxicity even when given after radiation exposure. We believe this approach could be of use in humans who are accidentally or intentionally exposed to lethal doses of radiation," said Sharpless, who is an associate professor of medicine and genetics at UNC's School of Medicine.

PQ relies on the use of potent and selective inhibitors of cellular enzymes called CDK4 and CDK6. Related drugs have been used extensively in humans with cancer, and CDK4/6 inhibitors are currently being tested in humans. Importantly, these drugs can be given as a pill, are chemically stable and have little toxicity. Therefore, such compounds could be stockpiled for use in the setting of an unexpected radiological disaster. The group showed that structurally different versions CDK4/6 inhibitors provided protection from radiation, whereas other types of kinase inhibitors did not.

Sharpless believe PQ may have a role in treating patients with cancer. Radiation is used in cancer therapy, and therefore PQ might benefit such patients. Also, several commonly used chemotherapy drugs cause bone marrow toxicity by damaging DNA, and therefore PQ might protect from chemotherapy toxicity in addition to radiation toxicity. A concern is that PQ might also protect a patient's tumor from the toxicity of therapeutic DNA damaging agents, but the Sharpless group showed that at least some types of cancer were not protected by inhibitors of CDK4/6. Bone marrow protection is a major issue in medical oncology, with billions of dollars of growth factors used annually in the US alone for this problem. In particular, PQ protects platelets and red cells, which are largely unmet needs in current clinical oncology.

UNC has filed patents related to these discoveries, which have been licensed to an RTP-startup company called G-Zero Therapeutics, which was co-founded in 2007 by Sharpless and researchers in Boston and San Franscisco.

This work was supported by the University of North Carolina Lineberger Comprehensive Cancer Center Mouse Phase I Unit and grants from the Golfers Against Cancer Foundation, the Ellison Medical Foundation, the Burroughs Wellcome Fund, and the National Institutes of. J.F. Bell was supported by a career development award from the V Foundation for Cancer Research.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sψren M. Johnson, Chad D. Torrice, Jessica F. Bell, Kimberly B. Monahan, Qi Jiang, Yong Wang, Matthew R. Ramsey, Jian Jin, Kwok-Kin Wong, Lishan Su, Daohong Zhou and Norman E. Sharpless. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. Journal of Clinical Investigtion, June 23, 2010 DOI: 10.1172/JCI41402

Cite This Page:

University of North Carolina School of Medicine. "Drug mitigates toxic effects of radiation in mice." ScienceDaily. ScienceDaily, 24 June 2010. <www.sciencedaily.com/releases/2010/06/100623123357.htm>.
University of North Carolina School of Medicine. (2010, June 24). Drug mitigates toxic effects of radiation in mice. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2010/06/100623123357.htm
University of North Carolina School of Medicine. "Drug mitigates toxic effects of radiation in mice." ScienceDaily. www.sciencedaily.com/releases/2010/06/100623123357.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) — America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) — A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins